• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Approval for pain reliever for osteoarthritic knees to be delayed

Article

Genzyme has to provide FDA with more data on Synvisc-One before the pain-relieving treatment for osteoarthritis can be approved.

Those who were waiting for the approval of Synvisc-One will have to wait a little longer. Genzyme Corp., which is applying for approval of the next generation of Synvisc (hylan G-F 20),

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.